|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPL26 |
Gene summary for RPL26 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPL26 | Gene ID | 6154 |
| Gene name | ribosomal protein L26 | |
| Gene Alias | DBA11 | |
| Cytomap | 17p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | P61254 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6154 | RPL26 | GSM4909281 | Human | Breast | IDC | 1.10e-39 | -2.65e-01 | 0.21 |
| 6154 | RPL26 | GSM4909282 | Human | Breast | IDC | 1.26e-105 | -5.75e-01 | -0.0288 |
| 6154 | RPL26 | GSM4909285 | Human | Breast | IDC | 2.01e-33 | -2.30e-01 | 0.21 |
| 6154 | RPL26 | GSM4909286 | Human | Breast | IDC | 6.74e-38 | -2.42e-01 | 0.1081 |
| 6154 | RPL26 | GSM4909287 | Human | Breast | IDC | 1.06e-87 | -6.99e-01 | 0.2057 |
| 6154 | RPL26 | GSM4909289 | Human | Breast | IDC | 9.69e-09 | -3.05e-01 | 0.1064 |
| 6154 | RPL26 | GSM4909290 | Human | Breast | IDC | 7.34e-75 | -5.17e-01 | 0.2096 |
| 6154 | RPL26 | GSM4909291 | Human | Breast | IDC | 3.55e-19 | -2.21e-01 | 0.1753 |
| 6154 | RPL26 | GSM4909292 | Human | Breast | IDC | 8.47e-23 | -5.89e-01 | 0.1236 |
| 6154 | RPL26 | GSM4909293 | Human | Breast | IDC | 9.12e-51 | -2.79e-01 | 0.1581 |
| 6154 | RPL26 | GSM4909294 | Human | Breast | IDC | 2.81e-33 | -3.54e-01 | 0.2022 |
| 6154 | RPL26 | GSM4909295 | Human | Breast | IDC | 3.59e-07 | -2.25e-01 | 0.0898 |
| 6154 | RPL26 | GSM4909296 | Human | Breast | IDC | 1.57e-06 | -1.35e-01 | 0.1524 |
| 6154 | RPL26 | GSM4909304 | Human | Breast | IDC | 7.89e-31 | -1.96e-01 | 0.1636 |
| 6154 | RPL26 | GSM4909307 | Human | Breast | IDC | 1.15e-41 | -2.77e-01 | 0.1569 |
| 6154 | RPL26 | GSM4909308 | Human | Breast | IDC | 1.48e-45 | -2.99e-01 | 0.158 |
| 6154 | RPL26 | GSM4909309 | Human | Breast | IDC | 1.53e-02 | -1.47e-01 | 0.0483 |
| 6154 | RPL26 | GSM4909311 | Human | Breast | IDC | 1.04e-08 | -1.92e-01 | 0.1534 |
| 6154 | RPL26 | GSM4909312 | Human | Breast | IDC | 1.41e-31 | -2.66e-01 | 0.1552 |
| 6154 | RPL26 | GSM4909315 | Human | Breast | IDC | 4.20e-44 | -3.82e-01 | 0.21 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:19019873 | Cervix | CC | regulation of cell cycle phase transition | 74/2311 | 390/18723 | 9.80e-05 | 1.27e-03 | 74 |
| GO:00714786 | Cervix | CC | cellular response to radiation | 41/2311 | 186/18723 | 1.41e-04 | 1.71e-03 | 41 |
| GO:20010209 | Cervix | CC | regulation of response to DNA damage stimulus | 46/2311 | 219/18723 | 1.92e-04 | 2.23e-03 | 46 |
| GO:00102126 | Cervix | CC | response to ionizing radiation | 34/2311 | 148/18723 | 2.23e-04 | 2.53e-03 | 34 |
| GO:00094112 | Cervix | CC | response to UV | 33/2311 | 149/18723 | 5.51e-04 | 5.29e-03 | 33 |
| GO:190179610 | Cervix | CC | regulation of signal transduction by p53 class mediator | 23/2311 | 93/18723 | 7.52e-04 | 6.72e-03 | 23 |
| GO:00086309 | Cervix | CC | intrinsic apoptotic signaling pathway in response to DNA damage | 24/2311 | 99/18723 | 7.93e-04 | 6.99e-03 | 24 |
| GO:19022294 | Cervix | CC | regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 12/2311 | 36/18723 | 8.74e-04 | 7.58e-03 | 12 |
| GO:19022538 | Cervix | CC | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 10/2311 | 29/18723 | 1.74e-03 | 1.31e-02 | 10 |
| GO:00457862 | Cervix | CC | negative regulation of cell cycle | 67/2311 | 385/18723 | 2.21e-03 | 1.59e-02 | 67 |
| GO:00459302 | Cervix | CC | negative regulation of mitotic cell cycle | 44/2311 | 235/18723 | 3.02e-03 | 1.99e-02 | 44 |
| GO:00714806 | Cervix | CC | cellular response to gamma radiation | 10/2311 | 31/18723 | 3.06e-03 | 2.01e-02 | 10 |
| GO:00427705 | Cervix | CC | signal transduction in response to DNA damage | 34/2311 | 172/18723 | 3.52e-03 | 2.27e-02 | 34 |
| GO:19019912 | Cervix | CC | negative regulation of mitotic cell cycle phase transition | 35/2311 | 179/18723 | 3.73e-03 | 2.38e-02 | 35 |
| GO:00427719 | Cervix | CC | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 12/2311 | 43/18723 | 4.71e-03 | 2.83e-02 | 12 |
| GO:20001341 | Cervix | CC | negative regulation of G1/S transition of mitotic cell cycle | 19/2311 | 84/18723 | 6.02e-03 | 3.43e-02 | 19 |
| GO:00346442 | Cervix | CC | cellular response to UV | 20/2311 | 90/18723 | 6.05e-03 | 3.44e-02 | 20 |
| GO:00103324 | Cervix | CC | response to gamma radiation | 14/2311 | 56/18723 | 6.93e-03 | 3.74e-02 | 14 |
| GO:00109482 | Cervix | CC | negative regulation of cell cycle process | 51/2311 | 294/18723 | 7.35e-03 | 3.94e-02 | 51 |
| GO:00315715 | Cervix | CC | mitotic G1 DNA damage checkpoint | 9/2311 | 30/18723 | 8.28e-03 | 4.28e-02 | 9 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPL26 | SNV | Missense_Mutation | c.149G>A | p.Arg50Gln | p.R50Q | P61254 | protein_coding | tolerated(0.11) | benign(0.029) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RPL26 | SNV | Missense_Mutation | c.377N>A | p.Arg126His | p.R126H | P61254 | protein_coding | tolerated(0.21) | benign(0.001) | TCGA-E2-A1LL-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | docetaxel | PD | |
| RPL26 | SNV | Missense_Mutation | novel | c.175N>G | p.Arg59Gly | p.R59G | P61254 | protein_coding | deleterious(0.02) | benign(0.131) | TCGA-VS-A8QA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| RPL26 | SNV | Missense_Mutation | rs757117420 | c.358N>A | p.Glu120Lys | p.E120K | P61254 | protein_coding | deleterious(0.04) | benign(0.013) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RPL26 | SNV | Missense_Mutation | c.377G>A | p.Arg126His | p.R126H | P61254 | protein_coding | tolerated(0.21) | benign(0.001) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| RPL26 | SNV | Missense_Mutation | novel | c.344N>A | p.Arg115His | p.R115H | P61254 | protein_coding | tolerated(0.11) | benign(0.003) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| RPL26 | SNV | Missense_Mutation | novel | c.87N>G | p.Ile29Met | p.I29M | P61254 | protein_coding | tolerated(0.06) | benign(0.024) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| RPL26 | SNV | Missense_Mutation | novel | c.92C>A | p.Ser31Tyr | p.S31Y | P61254 | protein_coding | deleterious(0) | benign(0.289) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| RPL26 | SNV | Missense_Mutation | novel | c.188A>C | p.Lys63Thr | p.K63T | P61254 | protein_coding | deleterious(0) | possibly_damaging(0.528) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RPL26 | SNV | Missense_Mutation | c.149N>A | p.Arg50Gln | p.R50Q | P61254 | protein_coding | tolerated(0.11) | benign(0.029) | TCGA-55-6968-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |